Antibody drug conjugate shows early promise in small cell lung cancer

Bookmark and Share
Published: 5 Jun 2016
Views: 2178
Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Rudin presents at ASCO 2016, early findings from a first-in-human clinical trial which showed that antibody drug conjugate (ADC) rovalpituzumab tesirine (Rova-T) demonstrated promising efficacy against recurrent small cell lung cancer (SCLC).

Read the news story for more.